Sm08502-onc-01

Author: mbew

August undefined, 2024

Webb28 nov. 2024 · A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors The safety and scientific validity of … WebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and …

Combination CDC-like kinase inhibition (CLK)/Dual-specificity …

Webb1 sep. 2024 · Characterization of SM08502, a small-molecule CLK inhibitor of Wnt activity. (A) SM08502 inhibited the activity of CLK kinases. CLK2, CLK3, and CDK1 kinase IC 50 s … WebbThe study will evaluate the safety, tolerability, PK, PD, and preliminary anti-tumor efficacy of SM08502 administered orally, once daily, following a 28-day treatment cycle (Part 1A). … the phobia of math

Omipalisib C25H17F2N5O3S - PubChem

Webb17 nov. 2024 · Drug: SM08502 Study Type Interventional Enrollment (Actual) 82 Phase Phase 1 Contacts and Locations This section provides the contact details for those … Webb[VIRTUAL] SM08502, a novel, small-molecule CDC-like kinase (CLK) inhibitor, demonstrates strong antitumor effects and Wnt pathway inhibition in castration-resistant prostate … WebbThis study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available. … sick from secondhand smoke

EPIC SCIENCES AND BIOSPLICE THERAPEUTICS ANNOUNCE

USA Life Sciences Database

Webb15 aug. 2024 · Abstract. Dysregulation of the cyclin D-CDK4/6-RB signaling axis is implicated in HR+ breast cancer (BC). While CDK4/6 inhibitors such as palbociclib … Webb27 jan. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and … the phobia of menWebb6 jan. 2024 · SM08502 inhibited the Wnt signaling pathway, both in vitro and in vivo, in colorectal cancer models. Inhibition of CLK2 and CLK3 affected alternative splicing, which underlies inhibition of aberrant Wnt signaling. SM08502 also demonstrated significant anti-tumor effects in xenograft models of gastrointestinal cancer. sick from stress at work

"Webb11 dec. 2024 · SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Samumed, today announced the dosing of the first cancer patient in its Phase 1 trial of SM08502, a small … " - Sm08502-onc-01

Sm08502-onc-01

The CLK inhibitor SM08502 induces anti-tumor activity

Webb29 sep. 2024 · add_box. SAN DIEGO, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Biosplice Therapeutics, Inc. (“Biosplice”), a clinical-stage biotechnology company pioneering … http://www.usalifesciences.com/us/portal/news_details.php?news_id=28606851k$SnKVXke2weSNs

Did you know?

Webb1 aug. 2024 · HEC265, SNGM, and Ishikawa-S33Y tumors all had significantly lower tumor volumes with combination of SM08502 and paclitaxel compared to single-agent … WebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and …

WebbSM08502-ONC-01: A Phase 1, Open-Label, Dose-Escalation, Dose-Finding Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects with … Webb27 jan. 2024 · As part of this relationship, Biosplice will leverage Epic’s comprehensive platform to characterize drug activity and patient response in Biosplice’s SM08502-ONC …

WebbCANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment Salubris Biotherapeutics Announces … Webb17 nov. 2024 · Drug: SM08502. SM08502 tablets to be administered orally. Arms, Groups and Cohorts. Experimental: Part 1A: Dose Escalation. Cohorts of subjects with advanced …

Webb30 jan. 2024 · Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK kinase modulation for major diseases, and …

Webb31 mars 2024 · In an iterative screening campaign of >1500 compounds, SM08502 was developed as a small-molecule CLK inhibitor with IC 50 values of 0.002 μM for CLK2 and … sick from sushi symptomsWebb6 jan. 2024 · Mel J. Yeates. SAN DIEGO—In late 2024, Samumed, LLC noted the publication of data demonstrating a novel mechanism of action for SM08502 in preclinical … the phobia of missing outWebbORG STUDY ID : SM08502-ONC-01 NCT ID : NCT03355066 Conditions Solid Tumor, Adult Interventions Purpose This study is an open-label, multi-center, dose-escalation, dose … sick from stress and anxietyWebbCancer stem cells (CSCs) are a subpopulation of tumor cells that can drive tumor initiation and can cause relapses. These cells are seen as drivers of tumor establishment and growth, often correlated to aggressive, heterogeneous and therapy-resistant tumors. Novel tumor-specific antigens (TSAs) and tumor-associated antigens (TAAs) specifically … the phobia of nightmaresWebb27 jan. 2024 · SAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CLK/DYRK … sick fs500 manualWebbAs part of this relationship, Biosplice will leverage Epic's comprehensive platform to characterize drug activity and patient response in Biosplice's SM08502-ONC-01 and SM08502-ONC-03 trials. "We are excited to partner with Epic in our biomarker development program" states Darrin Beaupre , MD, PhD, Chief Medical Officer, Oncology at Biosplice … the phobia of needlesWebbSAN DIEGO, Jan. 27, 2024 /PRNewswire/ -- Biosplice Therapeutics, Inc., a clinical-stage biotechnology company pioneering therapeutics based on CL sick from the sun